Onkologie, Hämatologie - Daten und Informationen

CUP-Syndrom: Literatur

Autor/en: G. Hübner
Letzte Änderung: 09.05.2005
  • Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN.
    Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.
    J Clin Oncol 1995;13:2094-2103. PM:7636553

  • Alberini JL, Belhocine T, Hustinx R, Daenen F, Rigo P.
    Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome).
    Nucl Med Commun 2003;24:1081-1086. PM:14508164

  • Alcalay M, Azais I, Brigeon B, Babin P, Vandermarcq P, Debiais F, et al.
    Strategy for identifying primary malignancies with inaugural bone metastases.
    Rev Rhum Engl Ed 1995;62:632-642. PM:8624672

  • Alizadeh AA, Ross DT, Perou CM, van de RM.
    Towards a novel classification of human malignancies based on gene expression patterns.
    J Pathol 2001;195:41-52. PM:11568890

  • Altman E, Cadman E.
    An analysis of 1539 patients with cancer of unknown primary site.
    Cancer 1986;57:120-124. PM:3940611

  • Argiris A.
    Update on chemoradiotherapy for head and neck cancer.
    Curr Opin Oncol 2002;14:323-329. PM:11981279

  • Argiris A, Smith SM, Stenson K, Mittal BB, Pelzer HJ, Kies MS, et al.
    Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary.
    Annals of Oncology 2003;14:1306-1311. PM:12881397

  • Atkin NB.
    Chromosome 1 aberrations in cancer.
    Cancer Genet Cytogenet 1986;21:279-285. PM:3513945

  • Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL.
    Unknown primary tumors metastatic to liver.
    JClin Oncol 1998;16:2105-2112. PM:9626210

  • Balana C, Manzano JL, Moreno I, Cirauqui B, Abad A, Font A, et al.
    A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.
    Annals of Oncology 2003:14:1425-1429. PM:12954583

  • Bar-Eli M, Abbruzzese JL, Lee-Jackson D, Frost P.
    p53 gene mutation spectrum in human unknown primary tumors.
    Anticancer Res 1993;13:1619-1623. PM:8239543

  • Bataini JP, Rodriguez J, Jaulerry C, Brugere J, Ghossein NA.
    Treatment of metastatic neck nodes secondary to an occult epidermoid carcinoma of the head and neck.
    Laryngoscope 1987;97:1080-1084. PM:3626734

  • Becouarn Y, Brunet R, Barbe-Gaston C.
    Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary.
    Eur J Cancer Clin Oncol 1989;25:861-865. PM:2500343

  • Bell CW, Pathak S, Frost P.
    Unknown primary tumors: establishment of cell lines, identification of chromosomal abnormalities, and implications for a second type of tumor progression.
    Cancer Res 1989;49:4311-4315. PM:2743318

  • Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al.
    Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.
    N Engl J Med 2004;350:1945-1952. PM:15128894

  • Blaszyk H, Hartmann A, Bjornsson J.
    Cancer of unknown primary: clinicopathologic correlations.
    APMIS 2003;111:1089-1094. PM:14678017

  • Bohuslavizki KH, Klutmann S, Kroger S, Sonnemann U, Buchert R, Werner JA, et al.
    FDG PET detection of unknown primary tumors.
    J Nucl Med 2000;41:816-822. PM:10809197

  • Braga L, Semelka RC, Danet IM, Venkataraman S, Woosley JT.
    Liver metastases from unknown primary site: demonstration on MR images.
    Magn Reson Imaging 2003;21:871-877. PM:14599537

  • Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, et al.
    Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II hellenic cooperative oncology group study.
    J Clin Oncol 2000;18:3101-3107. PM:10963638

  • Briasoulis E, Tsokos M, Fountzilas G, Bafaloukos D, Kosmidis P, Samantas E, et al.
    Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study.
    Anticancer Res 1998;18:1907-1914. PM:9677443

  • Buckhaults P, Zhang Z, Chen YC, Wang TL, St Croix B, Saha S, et al.
    Identifying tumor origin using a gene expression-based classification map.
    Cancer Res 2003;63: 4144-4149. PM:12874019

  • Carroll MC, Fleming M, Chitambar CR, Neuburg M.
    Diagnosis, workup, and prognosis of cutaneous metastases of unknown primary origin.
    Dermatol Surg 2002;28:533-535. PM:12081687

  • Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al.
    Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.
    N Engl J Med 2004;350:1937-1944. PM:15128893

  • Culine S, Fabbro M, Ychou M, Romieu G, Cupissol D, Pinguet F.
    Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site.
    Cancer 2002a;94:840-846. PM:11857320

  • Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, et al.
    Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site.
    J Clin Oncol 2002b;20:4679-4683. PM:12488413

  • Culine S, Fabbro M, Ychou M, Romieu G, Cupissol D, Pujol H.
    Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy.
    Annals of Oncology 1999;10:569-575. PM:10416007

  • D'Addario G, Morant R, Boehme C, Cerny T.
    Feasibility and toxicity of weekly Paclitaxel-Carboplatin in 131 patients with pretreated and non-pretreated solid tumors.
    Onkologie 2002;25:152-157. PM:12006766

  • de-Braud F, al-Sarraf M.
    Diagnosis and management of squamous cell carcinoma of unknown primary tumor site of the neck.
    Semin Oncol 1993;20:273-278. PM:8503023

  • DeYoung BR, Wick MR.
    Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach.
    Semin Diagn Pathol 2000;17:184-193. PM:10968704

  • Diaz-Rubio E, Evans TR, Tabemero J, Cassidy J, Sastre J, Eatock M, et al.
    Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.
    Annals of Oncology 2002;13:558-565. PM:12056706

  • Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR.
    A randomized Phase II trial in patients with carcinoma of an unknown primary site.
    Cancer 2001;91:592-597. PM:11169943

  • Eagan RT, Therneau TM, Rubin J, Long HJ, Schutt AJ.
    Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial.
    Am J Clin Oncol 1987;10:82-1085. PM:3548315

  • Eichhorn JH, Young RH, Scully RE.
    Nonpulmonary small cell carcinomas of extragenital origin metastatic to the ovary. Cancer 1993;71:177-186. PM:8380114

  • Erlander MG, Moore MW, Cotter P, et al.
    Molecular classification of carcinoma of unknown primary by gene expression profiling from formalin-fixed paraffin-embedded tissues.
    Proc ASCO 2004;23:9545.

  • Faure E, Riquet M, Lombe-Weta PM, Hubsch JP, Carnot F.
    Malignant mediastinal lymph node tumors with unknown primary cancers.
    Rev Mal Respir 2000;17:1095-1099. PM:11217505

  • Fizazi K, Voigt JJ, Lesimple T, et al.
    Carcinoma of unknown primary (CUP): are the tyrosine kinase receptors her-2, egf-r, and c-kit suitable targets for therapy?
    Proc ASCO 2003;3549.

  • Foroudi F, Tiver KW.
    Occult breast carcinoma presenting as axillary metastases.
    Int J Radiat Oncol Biol Phys 2000;47:143-147. PM:10758316

  • Giordana MT, Cordera S, Boghi A.
    Cerebral metastases as first symptom of cancer: a clinico-pathologic study.
    J Neurooncol 2000;50:265-273. PM:11263507

  • Giridharan W, Hughes J, Fenton JE, Jones AS.
    Lymph node metastases in the lower neck.
    Clin Otolaryngol 2003;28:221-226. PM:12755760

  • Glockner JF, White LM, Sundaram M, McDonald DJ.
    Unsuspected metastases presenting as solitary soft tissue lesions: a fourteen-year review.
    Skeletal Radiol 2000;29:270-274. PM:10883446

  • Gottschlich S, Schuhmacher O, Gorogh T, Hoffmann M, Maune S.
    [Analysis of the p53 gene status of lymph node metastasis in the head and neck region in occult primary cancer].
    Laryngorhinootologie 2000;79:434-437. PM:11005098

  • Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB.
    Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology.
    Radiother Oncol 2000;55:121-129. PM:10799723

  • Greco FA, Burris HA, III, Litchy S, Barton JH, Bradof JE, Richards P, et al.
    Gemcitabine, Carboplatin, and Paclitaxel for patients with carcinoma of unknown primary site: a minnie pearl cancer research network study.
    J Clin Oncol 2002;20:1651-1656. PM:11896116

  • Guarischi A, Keane T, Elhakim T.
    Metastatic inguinal nodes from an unknown primary neoplasm.
    Cancer 1987;59:572-577. PM:3791166

  • Hainsworth JD, Burris HA, III, Calvert SW, Willcutt NT, Scullin DC, Jr., Bramham J, et al.
    Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network.
    Cancer Invest 2001;19:335-339. PM:11405172

  • Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA.
    Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
    J Clin Oncol 1997;15:2385-2393. PM:9196154

  • Harstrick A, Schmoll HJ, Wilke H, Kohne-Wompner CH, Stahl M, Schober C, et al.
    Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma.
    J Clin Oncol 1991;9:1549-1555. PM:1651992

  • Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL.
    Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma.
    Clin Cancer Res 1999;5:3403-3410. PM:1058975

  • Hillen HF, Claessen S, van Mierlo A, et al.
    Genetic analysis reveals evidence for a clonal relationship between multiple tumors in individual patients with unknown primary tumor.
    Proc ASCO 2002;A:1810.

  • Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al.
    Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    J Clin Oncol 2001;19:2282-2292. PM:11304782

  • Hogan BA, Thornton FJ, Brannigan M, Browne TJ, Pender S, O'Kelly P, et al.
    Hepatic metastases from an unknown primary neoplasm (UPN): survival, prognostic indicators and value of extensive investigations.
    Clin Radiol 2002;57:1073-1077. PM:12475531

  • Hübner G, Rheinheimer M, Romanakis K, Zankl H.
    Cytogenetic analysis and comparative genome hybridization in carcinoma of unknown primary.
    Onkologie 2003;26:P1064.

  • Hübner G, Steinbach S, Kohne C, Stahl M, Kretzschmar A, Eimermacher A, et al.
    Paclitaxel (P) / carboplatin (C) versus gemcitabine (G) / vinorelbine (V) in patients with adeno- or undifferentiated carcinoma of unknown primary (CUP) - a randomized prospective phase-II-trial.
    Proc ASCO 2005;4089.

  • Hübner G, Tamme C, Wildfang I, Schöber C, Schmoll H-J.
    Management of patients with carcinoma of unknown primary (CUP-Syndrome).
    Journal of Cancer Research and Clinical Oncology 1990;116.

  • International Collaborative Ovarian Neoplasm Group (ICON-3).
    Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    Lancet 2002;360:505-515. PM:12241653

  • Issing WJ, Taleban B, Tauber S.
    Carcinoma of unknown primary, a survey in 167 patients.
    Laryngorhinootologie 2003;2:659-665. PM:14517763

  • Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyk K, Krzakowski M, Zatloukal P, et al.
    A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients.
    Annals of Oncology 2001;12:1375-1381. PM:11762807

  • Jereczek-Fossa BA, Jassem J, Orecchia R.
    Cervical lymph node metastases of squamous cell carcinoma from an unknown primary.
    Cancer Treat Rev 2004;30:153-164. PM:15023433

  • Kaufmann O, Fietze E, Dietel M.
    [Immunohistochemical diagnosis in cancer metastasis of unknown primary tumor]. Pathologe 2002;23:183-197. PM:12089786

  • Keith WN.
    From stem cells to cancer: balancing immortality and neoplasia.
    Oncogene 2004;23:5092-5094. PM:15107816

  • Koch WM, Bhatti N, Williams MF, Eisele DW.
    Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source.
    Otolaryngol Head Neck Surg 2001;124:331-333. PM:11241001

  • Kole AC, Nieweg OE, Pruim J, Hoekstra HJ, Koops HS, Roodenburg JL, et al.
    Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82:1160-1166. PM:9506364

  • Lapeyre M, Malissard L, Peiffert D, Hoffstetter S, Toussaint B, Renier S, et al.
    Cervical lymph node metastasis from an unknown primary: is a tonsillectomy necessary?
    Int J Radiat Oncol Biol Phys 1997;39:291-296. PM:9308930

  • Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielmann M, et al.
    Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients.
    Arch Intern Med 1988;148:2035-2039. PM:3046543

  • Lefèbvre JL, Coche-Dequeant B, Van JT, Buisset E, Adenis A.
    Cervical lymph nodes from an unknown primary tumor in 190 patients.
    Am J Surg 1990;160:443-446. PM:2221252

  • Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordonez NG, Abbruzzese JL.
    Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
    J Clin Oncol 1997;15:2056-2066. PM:9164218

  • Lloyd MS, Nash AG.
    'Occult' breast cancer.
    Ann R Coll Surg Engl 2001;83:420-424. PM:11777139

  • Lookingbill DP, Spangler N, Sexton FM.
    Skin involvement as the presenting sign of internal carcinoma. A retrospective study of 7316 cancer patients.
    J Am Acad Dermatol 1990;22:19-26. PM:2298962

  • Lortholary A, Abadie-Lacourtoisie S, Guerin O, Mege M, Rauglaudre GD, Gamelin E.
    [Cancers of unknown origin: 311 cases].
    Bull Cancer 2001;88:619-627. PM:11459709

  • Losa GF, Germa JR, Albareda JM, Fernandez-Ortega A, Sanjose S, Fernandez T, V. [Metastatic cancer presentation. Validation of a diagnostic algorithm with 221 consecutive patients].
    Rev Clin Esp 2002;202:313-319. PM:12093395

  • Macdonald AG, Nicolson MC, Samuel LM, Hutcheon AW, Ahmed FY.
    A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site.
    Br J ancer 2002;8:1238-1242. PM:11953879

  • Mahomed R, Rapoport BL, Uys A, et al.
    Age as a prognostic factor in metastatic cancer of unknown primary (CUP). Long term follow up results.
    Proc ASCO 2003;3590.

  • Maillefert JF, Tavernier C, Tebib J.
    Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin: A retrospective study.
    Cancer 2000;88:1759-1761. PM:10738237

  • Mantaka P, Baum RP, Hertel A, Adams S, Niessen A, Sengupta S, et al.
    PET with 2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) in patients with cancer of unknown primary (CUP): influence on patients' diagnostic and therapeutic management.
    Cancer Biother Radiopharm 2003;18:47-58. PM:12667308

  • Mariadason JM, Augenlicht LH, Arango D.
    Microarray analysis in the clinical management of cancer.
    Hematol Oncol Clin North Am 2003;17:377-387. PM:12737394

  • Mayordomo JI, Guerra JM, Guijarro C, Garcia-Prats MD, Gomez A, Lopez-Brea M, et al.
    Neoplasms of unknown primary site: a clinicopathological study of autopsied patients.
    Tumori 1993;79:321-324. PM:8116074

  • Mazzoccoli G, Carughi S, La Viola M, De Cata A, Puzzolante F, Camagna A, et al.
    [Cardiac metastasis of poorly differentiated adenocarcinoma of unknown primary site].
    Ital.Heart J 2002;3:1112-1116. PM:12506513

  • McKay CE, Hainsworth JD, Burris HA, et al.
    Treatment of metastatic poorly differentiated neuroendocrine carcinoma with paclitaxel/carboplatin/etoposide: a Minnie Pearl cancer research network phase II trial.
    Proc ASCO 2002:630.

  • Milliken ST, Tattersall MH, Woods RL, Coates AS, Levi JA, Fox RM, et al.
    Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens.
    Eur J Cancer Clin Oncol 1987;23:1645-1648. PM:2448145

  • Milovic M, Popov I, Jelic S.
    Tumor markers in metastatic disease from cancer of unknown primary origin.
    Med Sci Monit 2002;8:MT1-MT6.

  • Moraleda J, Grove N, Tran Q, et al.
    Gene expression data analytics with interlaboratory validation for identifying anatomical sites of origin of metastatic carcinomas.
    Proc ASCO 2004;23:9625.

  • Muir C.
    Cancer of unknown primary site.
    Cancer 1995;75:353-356. PM:8001006

  • Mukai H, Watanabe T, Ando M, Katsumata N.
    Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel.
    Int J Clin Oncol 2003;8:23-25. PM:12601538

  • Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, et al.
    Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
    J Clin Oncol 2003;21:968-975. PM:12637459

  • Nieder C, Gregoire V, Ang KK.
    Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple?
    Int J Radiat Oncol Biol Phys 2001;50:727-733. PM:11395241

  • Olson JA, Morris EA, Van Zee KJ, Linehan DC, Borgen PI.
    Magnetic resonance imaging facilitates breast conservation for occult breast cancer.
    Ann Surg Oncol 2000;7:411-415. PM:10894136

  • Patchell RA, Tibbs PA, Walsh JW, et al.
    A randomized trial of surgery in the treatment of single metastases to the brain.
    N Engl J Med 1990;322:494-500. PM:2405271

  • Pavlidis N, Briassoulis E, Bai M, Fountzilas G, Agnantis N.
    Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin.
    Anticancer Res 1995;15:2563-2567. PM:8669824

  • Perry A, Parisi JE, Kurtin PJ.
    Metastatic adenocarcinoma to the brain: an immunohistochemical approach.
    Human Pathology 1997;28:938-943. PM:9269830

  • Pouessel D, Culine S, Becht C, Ychou M, Romieu G, Fabbro M, et al.
    Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
    Cancer 2004;100:1257-1261. PM:15022294

  • Rades D, Kuhnel G, Wildfang I, Borner AR, Knapp W, Karstens JH.
    [The value of positron emission tomography (PET) in the treatment of patients with cancer of unknown primary (CUP)].
    Strahlenther Onkol 2001;177:525-529. PM:11680017

  • Rajendra T, Ann LK, Thomas J, Hong A, Chan C.
    Results of surgical treatment for cerebral metastases.
    J Clin Neurosci 2003;10:190-194. PM:12637047

  • Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, et al.
    Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
    J Natl Cancer Inst 2003;95:1118-1127. PM:12902441

  • Remick SC, Ruckdeschel JC.
    Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome.
    Med Pediatr Oncol 1992;20:89-99. PM:1310345

  • Ring BZ, Ross DT.
    Microarrays and molecular markers for tumor classification.
    Genome Biol 2002;3:2005. PM:12049658

  • Riquet M, Badoual C, le Pimpec BF, Dujon A, Danel C.
    Metastatic thoracic lymph node carcinoma with unknown primary site.
    Ann Thorac Surg 2003;75:244-249. PM:12537223

  • Ross MI, Cormier JN, Xing Y, et al.
    Prognosis and survival outcomes in melanoma patients with unknown primary site (MUP).
    Proc ASCO 2004;23:7544.

  • Rougraff BT.
    Evaluation of the patient with carcinoma of unknown origin metastatic to bone.
    Clin Orthop 2003;415:105-109. PM:14600599

  • Ruda R, Borgognone M, Benech F, Vasario E, Soffietti R.
    Brain metastases from unknown primary tumour: a prospective study.
    J Neurol 2001;248:394-398. PM:11437161

  • Saad ED, Abbruzzese JL.
    Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinoma.
    Crit Rev Oncol Hematol 2002;41:205-211. PM:11856596

  • Salvati M, Cervoni L, Raco A.
    Single brain metastases from unknown primary malignancies in CT- era.
    J Neurooncol 1995;23:75-80. PM:7623072

  • Scheithauer W, Kornek GV, Raderer M, Schull B, Schmid K, Kovats E, et al.
    Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.
    J Clin Oncol 2003;21:1307-1312. PM:12663719

  • Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ.
    Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
    J Clin Oncol 2002;20:582-587. PM:11786589

  • Schlagenhauff B, Stroebel W, Ellwanger U, Meier F, Zimmermann C, Breuninger H, et al.
    Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations.
    Cancer 1997;80:60-65. PM:9210709

  • Schnürch HG.
    [Tumor metastases in axillary lymph nodes in unknown primary tumor].
    Der Gynäkologe 1992;25:109-116. PM:1612513

  • Sengoz M, Abacioglu U, Salepci T, Eren F, Yumuk F, Turhal S.
    Extrapulmonary small cell carcinoma: multimodality treatment results.
    Tumori 2003;89:274-277. PM:12908782

  • Snee MP, Vyramuthu N.
    Metastatic carcinoma from unknown primary site: the experience of a large oncology centre.
    Br J Radiol 1985;58:1091-1095. PM:3842615

  • Srodon M, Westra WH.
    Immunohistochemical staining for thyroid transcription factor-1: A helpful aid in discerning primary site of tumor origin in patients with brain metastases.
    Human Pathology 2002;33:642-645. PM:12152164

  • Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, et al.
    Molecular classification of human carcinomas by use of gene expression signatures.
    Cancer Res 2001;61:7388-7393. PM:11606367

  • Sutherland CM, Chmiel JS, Bieligk S, Henson DE, Winchester DP.
    Patient characteristics, treatment, and outcome of unknown primary melanoma in the United States for the years 1981 and 1987.
    Am Surg 1996;62:400-406. PM:8615572

  • Tilanus Linthorst MM, Obdeijn AI, Bontenbal M, Oudkerk M.
    MRI in patients with axillary metastases of occult breast carcinoma.
    Breast Cancer Res Treat 1997;44:179-182. PM:9232276

  • Trosko JE.
    The role of stem cells and gap junctional intercellular communication in carcinogenesis.
    J Biochem Mol Biol 2003;36:43-48. PM:12542974

  • van de Pol M, van Aalst VC, Wilmink JT, Twijnstra A.
    Brain metastases from an unknown primary tumour: which diagnostic procedures are indicated?
    J Neurol Neurosurg Psychiatry 1996;61:321-323. PM:8795609

  • van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF.
    The unknown biology of the unknown primary tumour: a literature review.
    Annals of Oncology 2003;14:191-196. PM:12562643

  • van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992.
    Eur J Cancer 2002;38:409-413. PM:11818207

  • van-Ooijen B, Bontenbal M, Henzen-Logmans SC, Koper PC.
    Axillary nodal metastases from an occult primary consistent with breast carcinoma.
    Br J Surg 1993;80:1299-1300. PM:8242304

  • Velez A, Walsh D, Karakousis CP.
    Treatment of unknown primary melanoma.
    Cancer 1991;68:2579-2581. PM:1933805

  • Vlastos G, Jean ME, Mirza AN, Mirza NQ, Kuerer HM, Ames FC, et al.
    Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases.
    Ann Surg Oncol 2001;8:425-43. PM:11407517

  • Wax MK, Myers LL, Gabalski EC, Husain S, Gona JM, Nabi H.
    Positron emission tomography in the evaluation of synchronous lung lesions in patients with untreated head and neck cancer.
    Arch Otolaryngol Head Neck Surg 2002;128:703-707. PM:12049568

  • Wilke H, Korn M, Vanhofer U, Fink U, Stahl M, Preusser P, et al.
    Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer.
    J Infus Chemother 1996;6:123-126. PM:9229322

  • Zaren HA, Copeland EM..
    Inguinal node metastases.
    Cancer 1978;41:919-923. PM:638977

Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch: